GB201502110D0 - Use of alginate oligomers in the treatment of cystic fibrosis and other conditions associated with defective CFTR ion channel function - Google Patents
Use of alginate oligomers in the treatment of cystic fibrosis and other conditions associated with defective CFTR ion channel functionInfo
- Publication number
- GB201502110D0 GB201502110D0 GB201502110A GB201502110A GB201502110D0 GB 201502110 D0 GB201502110 D0 GB 201502110D0 GB 201502110 A GB201502110 A GB 201502110A GB 201502110 A GB201502110 A GB 201502110A GB 201502110 D0 GB201502110 D0 GB 201502110D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- treatment
- cystic fibrosis
- conditions associated
- ion channel
- channel function
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201502110A GB201502110D0 (en) | 2015-02-09 | 2015-02-09 | Use of alginate oligomers in the treatment of cystic fibrosis and other conditions associated with defective CFTR ion channel function |
US15/121,671 US20160361342A1 (en) | 2014-02-28 | 2015-02-27 | Use of alginate oligomers in the treatment of cystic fibrosis and other conditions associated with defective cftr ion channel function |
RU2016136449A RU2016136449A (en) | 2014-02-28 | 2015-02-27 | APPLICATION OF ALGINATE OLIGOMETES IN THE TREATMENT OF MUKOVISCIDOSIS AND OTHER CONDITIONS ASSOCIATED WITH THE DISTURBED FUNCTION OF CFTR ION CHANNELS |
EP15708474.0A EP3110426A1 (en) | 2014-02-28 | 2015-02-27 | Use of alginate oligomers in the treatment of cystic fibrosis and other conditions associated with defective cftr ion channel function |
JP2016554405A JP2017510563A (en) | 2014-02-28 | 2015-02-27 | Use of alginate oligomers in the treatment of cystic fibrosis and other pathologies associated with defective CFTR ion channel function |
CA2940560A CA2940560A1 (en) | 2014-02-28 | 2015-02-27 | Use of alginate oligomers in the treatment of cystic fibrosis and other conditions associated with defective cftr ion channel function |
KR1020167026840A KR20160119259A (en) | 2014-02-28 | 2015-02-27 | Use of alginate oligomers in the treatment of cystic fibrosis and other conditions associated with defective cftr ion channel function |
AU2015222051A AU2015222051A1 (en) | 2014-02-28 | 2015-02-27 | Use of alginate oligomers in the treatment of cystic fibrosis and other conditions associated with defective CFTR ion channel function |
PCT/EP2015/054207 WO2015128495A1 (en) | 2014-02-28 | 2015-02-27 | Use of alginate oligomers in the treatment of cystic fibrosis and other conditions associated with defective cftr ion channel function |
CN201580010273.7A CN106029079A (en) | 2014-02-28 | 2015-02-27 | Use of alginate oligomers in the treatment of cystic fibrosis and other conditions associated with defective cftr ion channel function |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201502110A GB201502110D0 (en) | 2015-02-09 | 2015-02-09 | Use of alginate oligomers in the treatment of cystic fibrosis and other conditions associated with defective CFTR ion channel function |
Publications (1)
Publication Number | Publication Date |
---|---|
GB201502110D0 true GB201502110D0 (en) | 2015-03-25 |
Family
ID=52746344
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB201502110A Ceased GB201502110D0 (en) | 2014-02-28 | 2015-02-09 | Use of alginate oligomers in the treatment of cystic fibrosis and other conditions associated with defective CFTR ion channel function |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB201502110D0 (en) |
-
2015
- 2015-02-09 GB GB201502110A patent/GB201502110D0/en not_active Ceased
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3634288A4 (en) | Electrode cured and manufactured in the body, and related methods and devices | |
IL267685A (en) | Method for modulating inflammasome activity and inflammation in the lung | |
EP3303634A4 (en) | Cas9 variants and methods of use thereof | |
EP3359644A4 (en) | Novel rna-guided nucleases and uses thereof | |
GB201504878D0 (en) | Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion | |
IL250718A0 (en) | Treatment of inflammation, respiratory tract infections and cystic fibrosis | |
EP3200808A4 (en) | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy | |
EP2968285A4 (en) | Compounds and methods for the treatment of cystic fibrosis | |
SG10201606961TA (en) | Quantum-dot spectrometers for use in biomedical devices and methods of use | |
HK1256419A1 (en) | Acetamide thienotriazolodiazepines and uses thereof | |
EP3355983A4 (en) | Dry eye treatment devices and methods | |
IL268210A (en) | Use of gaboxadol in the treatment of tinnitus | |
EP3296325A4 (en) | Elliptical, needle-shaped, or rod-shaped crosslinked polymer particles, and use thereof | |
EP3139949A4 (en) | Methods and compositions for treating cystic fibrosis | |
IL267639A (en) | Oncolytic viruses and therapeutic molecules | |
EP3193875A4 (en) | Levocetirizine and montelukast in the treatment of inflammation mediated conditions | |
EP3463324A4 (en) | Levocetirizine and montelukast in the treatment of radiation-mediated conditions | |
HK1257679A1 (en) | Treatment and prevention of neuronal cell loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate | |
EP3243382A4 (en) | Waterless livewell apparatus and refrigeration appliance provided with the waterless livewell apparatus | |
EP3302207A4 (en) | Surface treatment apparatuses and methods | |
EP3166626A4 (en) | Materials and methods for treating disorders associated with sulfatase enzymes | |
ZA201708223B (en) | Endostatin fragments and variants for use in treating fibrosis | |
IL270701A (en) | Neurotrophins for use in the treatment of hearing loss | |
EP3331488A4 (en) | Improved hyaluronan and modified-hyaluronan in biomedical applications | |
EP3458157A4 (en) | Methods for treating disorders associated with fibrosis and systemic sclerosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |